Navigation Links
Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
Date:4/25/2008

MISSISSAUGA, ON, April 25 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), today announced that on April 24, 2008, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, Vasogen was not in compliance with Marketplace Rule 4310(c)(4) (the "Rule"). In accordance with the NASDAQ Marketplace Rule 4310(c)(8)(D), Vasogen is provided a compliance period of 180 calendar days, or until October 21, 2008, to regain compliance with this requirement. If the Rule requirements cannot be demonstrated by October 21, 2008, but Vasogen continues to meet the NASDAQ Capital Market initial listing criteria, other than the bid price, NASDAQ will provide an additional 180 calendar days to meet the Rule requirements. The notice has no effect on the listing of Vasogen's common stock at this time, and its common stock will continue to trade on the NASDAQ Capital Market under the symbol "VSGN", as well as on the Toronto Stock Exchange under the symbol "VAS".

Vasogen can regain compliance with the Rule if the bid price of its common stock closes at $1.00 or higher for a minimum of ten consecutive business days during the compliance period, although NASDAQ may, in its discretion, require the Company to maintain a minimum closing bid price of at least $1.00 per share for a period in excess of ten consecutive business days (but generally no more than 20 consecutive business days) before determining that Vasogen has demonstrated the ability to maintain long-term compliance. If Vasogen is not eligible for an additional compliance period, or does not regain compliance during
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  Decision Resources Group finds that the majority ... the United States believe that ... be the level of savings achievable by their ... cost to patients. Payers plan to leverage preferential ... expectations in order to encourage physician prescribing of ...
(Date:7/30/2014)... July 30, 2014 A study presented ... safety and efficacy of CSL Behring,s C1 Inhibitor ... transplants in highly sensitized patients. C1-INH is a ... complement system. The study shows that ... in the levels of complement components 3 and ...
(Date:7/30/2014)... Chicago Bears are excited to announce the team,s partnership ... effort to raise awareness of skin cancer. Through this ... skin cancer screenings at a preseason fan event on ... me™ is an educational campaign designed to inform the public, ... cancer, and encourages people to get screened by a ...
(Date:7/30/2014)... LONDON , July 30, 2014  Replikins Ltd. ... structure of the Ebola virus. Before the current outbreaks, ... Replikins per 100 amino acids) between 1995 and 2002 ... 2010, threefold in 2012, and sixteen-fold in 2013, thus ... the past, this technology has been shown to be ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4
... such tests on samples sent in from all over Spain. ... truly personalised medicine. And researchers are exploring new ways to ... scale: the genes that are being read or transcribed; the ... the length of the telomeres capping its chromosomes. The ...
... or ultracapacitors, differ from regular capacitors that you would ... store substantially higher amounts of charges. They have garnered ... discharge faster than batteries, yet they are still limited ... energy density of batteries. An EC that combines the ...
... March 16, 2012  Tarsa Therapeutics, Inc. today announced ... financing led by new investor Foresite Capital.  James ... Tarsa,s Board of Directors.  Tarsa,s existing venture capital ... Partners—all participated in the new financing round.  ...
Cached Biology Technology:CNIO researchers take part in the most comprehensive personalized medicine study performed to date 2CNIO researchers take part in the most comprehensive personalized medicine study performed to date 3Researchers develop graphene supercapacitor holding promise for portable electronics 2Researchers develop graphene supercapacitor holding promise for portable electronics 3Researchers develop graphene supercapacitor holding promise for portable electronics 4Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin 2Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin 3Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin 4
(Date:7/30/2014)... study of dominance in female baboons suggests that the route ... mom, and to have lots of supportive sisters. , A ... strength, but by the rank of her mother - the ... be. For this reason, dominance rank in female baboons is ... mothers are guaranteed a good spot in the pecking order, ...
(Date:7/30/2014)... The Jackson Laboratory has received a pledge of $1 ... and name the Laboratory,s new Neurobehavioral Biometry Center. ... Biometry Center will enable the Laboratory to develop a ... with the ultimate goal of accelerating the pace of ... will serve as a premier resource for the Laboratory ...
(Date:7/30/2014)... Clemson University associate professor Andrew S. Mount, performed cutting-edge ... way for novel anti-fouling paint for ships and boats ... , The team,s findings, published in Nature ... barnacles that attaches to a wide variety of surfaces ... as an underwater heavy-duty adhesive. , "In previous research, ...
Breaking Biology News(10 mins):Supportive moms and sisters boost female baboon's rank 2Supportive moms and sisters boost female baboon's rank 3Rossi Foundation pledges $1M for JAX neurobehavioral research center 2Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2
... project to teach undergraduate students about network analysis, turned ... to analyze a National Basketball Association (NBA) basketball team,s ... discovered it is possible to quantify both a team,s ... in an online November issue of PLOS ONE ...
... research from Georgia Aquarium and Georgia Institute of Technology ... can be used to determine the health status of ... fish species. The study, led by Dr. Alistair Dove, ... an adjunct professor at Georgia Tech, found that the ...
... Robertson (Rob) McClung is not your typical clock-watcher. His ... based on a 24-hour period. Living organisms depend upon ... rotation and the recurring changes it imposes on the ... anticipate the changes and adapt to them by modifying ...
Cached Biology News:Basketball teams offer insights into building strategic networks 2New whale shark study used metabolomics to help understand shark and ray health 2Dartmouth research: The clocks are ticking and the climate is changing 2Dartmouth research: The clocks are ticking and the climate is changing 3Dartmouth research: The clocks are ticking and the climate is changing 4
... causing shortages in your laboratory or fellow ... cause unwanted distractions, problems and delays. • ... hard work and endeavour! Bring us your ... and market it internationally. We work under ...
... Perhaps sheer in-house demand is causing shortages ... precious antibody. This can cause unwanted distractions, ... Receive royalties for your hard work ... let us build it up,and market it ...
Topoisomerase I...
...
Biology Products: